Grufity logo
Grufity logo
CNSP

CNSP - CNS Pharmaceuticals Inc Stock Price, Fair Value and News

$5.70+0.85 (+17.53%)
Market Closed as of 31 Jul 2026, 04:00 pm ET

Price Targets

CNSP Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CNSP Price Action

Last 7 days

9.0%

Last 30 days

21.8%

Last 90 days

146.8%

Trailing 12 Months

-28.6%

CNSP RSI Chart

CNSP Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CNSP Valuation

Market Cap

8.3M

Price/Earnings (Trailing)

-0.51

Price/Sales (Trailing)

159.44

Price/Free Cashflow

-0.47

CNSP Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

CNSP Fundamentals

CNSP Revenue

Revenue (TTM)

27.7K

CNSP Earnings

Earnings (TTM)

-16.5M

Earnings Growth (Yr)

-14.78%

Earnings Growth (Qtr)

17.11%

CNSP Profitability

Return on Equity

-23.3K%

Return on Assets

-354.3%

Free Cashflow Yield

-214.95%

CNSP Investor Care

Shares Dilution (1Y)

543.19%

Diluted EPS (TTM)

-26.87

Revenue & Growth

How CNS Pharmaceuticals Inc generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2024----
2023---27.7K
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About CNS Pharmaceuticals Inc

CNSP
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.
 CEO
 WEBSITEcnspharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES3

CNS Pharmaceuticals Inc Frequently Asked Questions

CNSP is the stock ticker symbol of CNS Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Jul 31 2026, market cap of CNS Pharmaceuticals Inc is 8.33 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Jul 31 2026, CNSP's PE ratio (Price to Earnings) is -0.51 and Price to Sales (PS) ratio is 159.44. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CNSP PE ratio will change depending on the future growth rate expectations of investors.